Seité Sophie, Zelenkova Hana, Martin Richard
La Roche-Posay Dermatological Laboratories, Asnières, France.
DOST, Private Clinic of Dermatovenereology, Svidnik, Slovakia.
Clin Cosmet Investig Dermatol. 2017 Jan 12;10:25-33. doi: 10.2147/CCID.S121910. eCollection 2017.
We speculated that an emollient supplemented with a biomass of nonpathogenic bacteria such as , grown in a medium containing thermal spring water (LRP-TSW); (LRP- biomass [LRP-VFB]), could have a beneficial effect for patients with atopic dermatitis (AD).
This double-blind, randomized, comparative study was conducted with 60 patients with moderate AD. Before starting the study, participants were pretreated for 15 days with drug therapy to improve their SCORing Atopic Dermatitis (SCORAD) by at least 25%. On Day 1, the eligible patients were randomized to either the emollient containing LRP-VFB associated with mannose (Product A) or another emollient (product B) and were treated twice daily for 1 month. Recurrence of flare-ups and microbial communities were characterized from swabs taken at Day 1 and Day 28, under axenic conditions, from affected (AF) and proximal unaffected (UAF) skin areas.
At Day 1, the average SCORAD of each group and the microbial communities of AF and UAF areas for each participant were similar. One month after the end of the therapeutic treatment (Day 28), the average evolution of SCORAD at Day 28 compared to Day 1 of patients treated with product A was significantly lower than that of the patients treated with product B. A significantly increased level of genus was noticed in the group treated with product A (versus product B). On the other hand, the level of genus increased between Day 1 and Day 28 in the group treated with product B, but not in the group treated with product A. Interestingly, these differences were more pronounced for patients in relapse, and the associated SCORAD worsening was less in the group treated with product A versus the group treated with product B.
This study demonstrated that a specific emollient containing a biomass of non-pathogenic bacteria grown in a medium containing TSW and associated with a selected carbon source is able to normalize skin microbiota and significantly reduce the number and severity of flare-ups compared with another emollient.
我们推测，一种添加了在含有温泉水的培养基（LRP - TSW）中培养的非致病细菌生物量的润肤剂；（LRP - 生物量[LRP - VFB]），可能对特应性皮炎（AD）患者有益。
这项双盲、随机、对照研究纳入了60例中度AD患者。在研究开始前，参与者接受了15天的药物治疗，以使他们的特应性皮炎评分（SCORAD）至少提高25%。在第1天，符合条件的患者被随机分为两组，一组使用含有与甘露糖相关的LRP - VFB的润肤剂（产品A），另一组使用另一种润肤剂（产品B），并每天治疗两次，持续1个月。在无菌条件下，从第1天和第28天采集的受影响（AF）和近端未受影响（UAF）皮肤区域的拭子中，对皮疹复发情况和微生物群落进行特征分析。
在第1天，每组的平均SCORAD以及每个参与者的AF和UAF区域的微生物群落相似。治疗结束1个月后（第28天），与产品B治疗的患者相比，产品A治疗的患者在第28天的SCORAD相对于第1天的平均变化显著更低。在产品A治疗组（与产品B相比）中， 属的水平显著增加。另一方面，产品B治疗组在第1天至第28天 属的水平有所增加，但产品A治疗组没有。有趣的是，这些差异在复发患者中更为明显，并且与产品B治疗组相比，产品A治疗组的相关SCORAD恶化程度更小。
本研究表明，与另一种润肤剂相比，一种含有在含有TSW的培养基中培养并与选定碳源相关的非致病细菌生物量的特定润肤剂能够使皮肤微生物群正常化，并显著减少皮疹发作的次数和严重程度。
